Esophageal cancer is one of the common malignant tumors in human. About 300 000 people die of esophageal cancer each year worldwide. China is a highincidence area of esophageal cancer, and about 150 000 people die of esophageal cancer every year, accounting for nearly a quarter of all cancer deaths. The incidence of esophageal cancer in different nations varies widely. In America, the incidence of esophageal cancer is higher in nonwhite males (20.5/100 000) than in white males (5.8/100 000); the incidence is higher in Chinese and Japanese than in European and American. Radiotherapy plays an important role in the treatment of esophageal cancer. In recent 20 years, the radiation oncologists in China have been making unremitting study to improve the survival rate of patients with esophageal cancer by radiotherapy, and underwent conventional fractionated radiotherapy, nonconventional fractionated radiotherapy, combined radiochemotherapy, and threedimensional conformal radiotherapy, but the survival rate had no significant improvement. In 2009, NCCN recommended concurrent radiochemotherapy as the nonsurgical treatment for esophageal cancer, which is based on clinical studies such as the RTOG 8501 and RTOG 9405 [14] . In China, esophageal cancer has unique geographical and pathologic features, with the morbidity and mortality relatively high in rural areas in Hebei, Shanxi, 窑Esophageal Cancer Column窑 A total of 56 literatures about radiotherapy alone for esophageal squamous cell carcinoma published in the core journals in China between January 1994 and December 2009 were enrolled (Tables 1 and 2 ) [661] . The enrollment criteria included: (1) patients with a definite pathologic diagnosis of esophageal squamous cell carcinoma; (2) patients received radiotherapy alone or nonsurgical comprehensive treatment based on radiotherapy; (3) randomized trials with more than 80 patients and retrospective studies with more than 100 patients; (4) clinical research literatures published in the core journals in China; (5) at least 1year survival rate was reported; (6) the recent one of repetitive literatures.
The enrolled literatures were screened by Meta analysis, and the screening criteria included: (1) randomized clinical trials; (2) at least 40 patients in each designed study group; (3) with at least 3year survival rate; (4) no less than 2 points of literature quality assessed by Jadad score [62] .
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The local control rates were reported in 31 of the 56 literatures. The 1, 2, 3, and 5year average overall local control rates were (73.04 依 13.37)% , (61.60 依 15.50)% , (51.77 依 15.00)%, and (50.15 依 21.36)%, respectively.
Acute radiation esophagitis was reported in 32 of the 56 literatures, and the 15year overall incidence of acute esophageal reaction was (44.84 依 25.71)% . The grade of acute esophageal reaction was described in 13 literatures, Year and the incidence of acute esophageal reaction more than Grade II was (35.93 依 22.90)% . Through the analysis by groups in 32 literatures, the incidence of radiation esophagitis was (26.84 依 13.12)% in conventional fractionated radiotherapy group, (53.72 依 21.82)% in latecourse hyperfractionated radiotherapy group, (61.33 依 28.69)% in radiochemotherapy group, and (40.31 依 27.22)% in other fractionated radiotherapy group. Radiation pneumonitis, radiation cardiac injury, and other acute radiation reactions were reported in fewer than 10 literatures, so they were not compared and analyzed.
The late esophageal reactions, including perforation and bleeding, were described in 23 of the 56 literatures (without clear grade), and the 15year overall incidence of late esophageal reaction was (5.13 依 4.07)%. Through the analysis by groups in 23 literatures, the incidence of late esophageal reactions was (5.66 依 3.42)% in conventional fractionated radiotherapy group, (4.53 依 4.07)% in late course hyperfractionated radiotherapy group, (2.24 依 1.31)% in radiochemotherapy group, and (7.34 依 5.06)% in other fractionated radiotherapy group. The radiation fibrosis of the esophagus and lungs, radiation myelitis, and radiation cardiac injury were reported in fewer than 5 literatures, so these late reactions were not compared and analyzed.
A total of 13 literatures involving 1458 patients were selected, of which 725 patients received conventional fractionated radiotherapy and 733 received concurrent radiochemotherapy. The analysis showed that the 3year survival rate of concurrent radiochemotherapy group was better than that of conventional fractionated radiotherapy group, with a RR value of 1.37 (Figure 3 ). Publication bias analysis showed that the P value of Begg rank correlation test was 0.360 and that of Egger linear regression was 0.77, without significant publication bias ( Figure 4 ). Sensitivity analysis was conducted and the studies with a Jadad score of 2 were reevaluated, and RR value was 1.38 with a sound result. Figure 3 Forest plots of CF and CCRT groups A total of 7 literatures involving 763 patients were selected, of which 377 patients received conventional fractionated radiotherapy and 386 received latecourse accelerated hyperfractionated radiotherapy. The analysis showed that the 3year survival rate of latecourse accelerated hyperfractionated radiotherapy group was better than that of conventional fractionated radiotherapy group, with a RR value of 1.31 ( Figure 5 ). Publication bias analysis showed that the P value of Begg rank correlation test was 0.035 and that of Egger linear regression was 0.007, with statistical difference and publication bias existed. Sensitivity analysis was conducted and the studies with a Jadad score of 2 were reevaluated, and RR value was 1.32 with a sound result. 
Figure 5 Forest plots of CF and LACH groups
A total of 5 literatures involving 539 patients were selected, of which 267 patients received latecourse accelerated hyperfractionated radiotherapy and 272 received concurrent radiochemotherapy. The analysis showed that the 3year survival rate of concurrent radiochemotherapy Figure 6 Forest plots of LACH and CCRT groups group was better than that of latecourse accelerated hyperfractionated radiotherapy group, with a RR value of 1.25 ( Figure 6 ). Publication bias analysis showed that the P value of Begg rank correlation test was 0.085 and that of Egger linear regression was 0.082, without statistical difference. Sensitivity analysis was conducted and the studies with a Jadad score of 2 were reevaluated, and RR value was 1.23 with a sound result.
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Gao XS (2002) Duan YJ (2003) Li XM (2003) Ya HX (2006) Zhang H (2006) Ove rall (I鄄 squared = 0.0%, P = 0.706) Esophageal cancer is one of the highincidence tumors in China, and radiotherapy is one of the main treatments of esophageal cancer. Although the radiotherapy for esophageal cancer has been tried in various forms, the treatment efficacy has not been satisfying. The 5year survival rate of the patients received conventional fractionated radiotherapy has been hovering around 10%. Since 1996, the radiotherapy for esophageal cancer developed rapidly in China, so we pooled and analyzed the results of radiotherapy for esophageal cancer in recent 15 years to provide reference and theoretical experience for the future treatment of esophageal cancer. Considering the findings of small sample studies might affect the analysis of the results, we calculated the sample number based on 琢 = 0.05, 茁 = 0.2, and equivalent standard (啄 ) = 0.2, and 39 patients were required for each group. So we only selected randomized controlled trials with more than 80 patients and retrospective studies with more than 100 cases and analyzed the literatures.
Our results showed that the overall 3 and 5year survival rates of patients with esophageal cancer treated by radiotherapy had greatly improved compared with before 1996, but had no significant improvement since 1997, with 3year survival rate hovering around 30% and 5year survival rate hovering around 20 %. After 1996, with the exploration of a variety of radiotherapy methods, the reported 3year survival rate was improved as compared with that of patients treated by conventional radiotherapy, but Figure 2 shows that the 3year survival rate in 15 years maintained a relatively stable level (the highamplitude change appeared in 2006 was considered to be related with too few conventional fractionated radiotherapy reported in the same year), and latecourse accelerated fractionation, combined radiochemotherapy and other treatments including combined brachytherapy and wholecourse accelerated hyperfractionated radiotherapy resulted in the survival rates with relatively large fluctuations, with the 3year survival rate fluctuating more than 20% . After 2001, with the increase of concurrent radiochemotherapy studies, the 3year survival rate showed a steady increasing trend, which is considered to be associated with increased chemotherapy drugs, gradually matured treatment technologies, deep understanding of disease, and other medical and social factors.
The comparative analysis showed that acute radiation esophagitis was reported more in concurrent radiochemotherapy and latecourse accelerated hyperfractionated radiotherapy, with an incidence above 50%. Late reactions, including perforation and bleeding, had a highest incidence in other groups including combined brachytherapy and accelerated hyperfractionated radiotherapy, but in 15 years, the average incidence of perforation and bleeding in conventional fractionated radiotherapy group was slightly higher than that in latecourse hyperfractionated radiotherapy and radiochemotherapy groups, and esophageal late reactions remained a relatively stable level. This indicates that radiochemotherapy and latecourse hyperfractionated radiotherapy increase acute reactions to a certain extent, but do not increase late reactions.
Meta analysis showed that the 3year survival rates of concurrent radiochemotherapy and latecourse accelerated hyperfractionated radiotherapy groups were higher than that of conventional fractionated radiotherapy group, and particularly concurrent radiochemotherapy had a greater advantage. No publication bias was found, and the results showed that concurrent radiochemotherapy was also suitable for Chinese patients with esophageal cancer. Liu . [63] reported that the average 5year survival rate of esophageal cancer patients after surgical treatment was 27.7% (21.2%43.5%) in China, which was close to (23.31 依 10.21)% in our study. In 2009, the NCCN guideline recommended concurrent radiochemotherapy or preoperative radiochemotherapy as the first choice for locally advanced esophageal cancer, suggesting that concurrent radiochemotherapy has a clear advantage in the treatment of esophageal cancer, which is consistent with the results of this Meta analysis. Therefore, the Chinese patients with nonoperative esophageal cancer may also get large benefit from concurrent radiochemotherapy. However, in literatures the chemotherapy regimen selection in concurrent radiochemotherapy has no unified standard (both singledrug and combination regimens have been reported), and acute radiation esophageal reactions are mostly found in concurrent radiochemotherapy group, with few reports of longterm toxicities. Therefore, the best drugs and dose of concurrent radiochemotherapy for Chinese patients still need to be explored by large sample standardized randomized controlled clinical study. In this study, the bias analysis of literatures with latecourse accelerated hyperfractionated radiotherapy and conventional fractionated radiotherapy showed evidence of publication bias, which might be related to less selected literatures, and the efficacy of latecourse accelerated hyperfractionated radiotherapy needs to be confirmed by more detailed Meta analysis or clinical trials.
Radiotherapy is one of the main treatments of advanced esophageal cancer, but the analysis results of the literatures in China in 15 years show that the longterm survival is still far from ideal, and concurrent radiochemotherapy shows a treatment advantage. However, the treatment modality and chemotherapy drugs suitable for Chinese patients, specific program of comprehensive treatment and individualized treatment still need to be further studied.
